Why Solazyme Inc Slipped This Morning
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.
What: Shares of Solazyme Inc slipped about 2% this morning after Goldman Sachs downgraded the renewable oil company from Buy to Neutral.
So what: Along with the downgrade, analyst Brian Lee reiterated his price target of $13.50, representing about 10% worth of upside to yesterday's close. While momentum traders might be attracted to the stock's strength in recent months, Lee thinks that much of Solazyme's prospects are already baked into the valuation.
Now what: According to Goldman, Solazyme's risk/reward trade-off is pretty balanced at this point. "We believe SZYM has executed well vs. peers, with its first two commercial- scale facilities now within months of both being online and delivering volume," noted Lee. "That said, we think this catalyst is already reflected, given the stock's c.30% move since the end of Jan., and we are more guarded on the near-term path for catalysts given financial performance is likely to remain muted." Of course, when you consider Solazyme's rock-solid balance sheet and still-compelling long-term prospects, I'd take Goldman's downgrade with a grain of salt.
No friend of OPEC
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report reveals the company we're calling OPEC's Worst Nightmare. Just click HERE to uncover the name of this industry-leading stock... and join Buffett in his quest for a veritable LANDSLIDE of profits!
The article Why Solazyme Inc Slipped This Morning originally appeared on Fool.com.Brian Pacampara has no position in any stocks mentioned. The Motley Fool owns shares of Solazyme. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.